# US Apheresis Market

> Us Apheresis Service Market Research Report Market Research Report Information By service type (Donor/Automated Apheresis, Therapeutic Apheresis, and Stem Cell Collection and Processing), By Application (Neurological Disorders, Autoimmune Disorders, Hematologic Disorders, Oncology, Metabolic Toxicology Disorders, Infectious Diseases, Cardiovascular Disorders, and Others), By End User (Hospitals, Blood Banks, Specialty Clinics, Research Laboratories, and Biotechnology Pharmaceutical Companies) and by Region (North, South, Midwest, and West) –Market Forecast Till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 9.3%
- **2024:** $ 252 Million
- **2025:** $ 275.44 Million
- **2035:** $ 670 Million
- **Key Players:** Fresenius Kabi (DE), Terumo BCT (JP), Haemonetics Corporation (US), Grifols S.A. (ES), Cellerant Therapeutics (US), Kawasumi Laboratories (JP), Asahi Kasei Medical (JP), Medtronic (IE), Blood Centers of America (US)

**Report ID:** MRFR/MED/16369-CR · **Pages:** 86 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** January 13, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-apheresis-market-17897

---

## Market Summary

## **Us Apheresis Service Market Overview**

**The US Apheresis Service Market size was valued at USD 760.91 million in 2024. The Us Apheresis Service Market research report industry is projected to grow from USD 812.50 million in 2025 to USD 1,832.77 million by 2035, exhibiting a Compound Annual Growth Rate (CAGR) of 8.47% during the forecast period (2024 – 2035).**

Increasing prevalence of chronic diseases, rising demand for plasma-derived therapies, and favorable reimbursement policies are driving the Us Apheresis Service Market. As per an Analyst at MRFR, "The increasing prevalence of chronic diseases, rising demand for plasma-derived therapies, and favorable reimbursement policies are fueling the growth of the US [Apheresis Market](../../../reports/apheresis-market/companies)."

Additionally, high procedure costs, safety concerns in blood transfusions, and the recruitment of voluntary non-remunerated donors are restraining factors for the market. However, the increasing demand for platelet-rich plasma therapy and apheresis for leukemia and pediatric patients will provide growth opportunities for the market in the future.

Source: Secondary Research, Primary Research, _Market Research Future_ Database, and Analyst Review

## **Us Apheresis Service Market Trends**

### **Increasing Demand For Platelet-Rich Plasma Therapy**

**Platelet-rich plasma (PRP) therapy** has garnered significant attention in recent years, particularly within the fields of orthopedics, dermatology, and sports medicine. The therapy involves using a patient’s own platelets, which are concentrated from their blood, to accelerate healing and tissue regeneration.

However, the growing demand for PRP therapy has also led to an increased need for apheresis services, as this technique is often employed to collect platelets from healthy blood donors for PRP treatments. Apheresis allows for the efficient extraction of platelets.

These platelets are then used in PRP therapy to treat a variety of conditions such as musculoskeletal injuries, hair loss, and even skin rejuvenation. In orthopedics, PRP therapy is commonly used to treat tendon injuries, ligament sprains, and osteoarthritis.

It works by promoting tissue healing and reducing inflammation. In dermatology, it has gained popularity for its ability to stimulate hair growth in patients with androgenic alopecia (male or female pattern baldness) and improve the appearance of the skin by reducing wrinkles.

It also promotes collagen production. As the clinical applications of PRP therapy expand and its regenerative properties are increasingly recognized, more healthcare providers are incorporating them into treatment regimens. This shift is creating substantial demand for platelet collections, which in turn, is fueling the need for apheresis services.

## **Us Apheresis Service Market Segment Insights**

### **Us Apheresis Service Market Research Report Service Type Insights**

Based on service type, the US Apheresis Service Market has been segmented into Donor/Automated Apheresis, Therapeutic Apheresis, and Stem Cell Collection and Processing. The **Therapeutic Apheresis** segment held the largest market share in 2024.

The Stem Cell Collection and Processing segment is the fastest-growing segment during the forecast period (2025 -2035). The U.S. Apheresis Service Market, segmented by service type, includes Donor/Automated Apheresis, Therapeutic Apheresis, and Stem Cell Collection and Processing.

In 2024, Therapeutic Apheresis dominated the market share, driven by its critical role in treating autoimmune and neurological disorders, as well as its increasing adoption in hospitals and specialty clinics. This segment's growth is further supported by rising prevalence of chronic diseases and advancements in apheresis technology.

However, the fastest-growing segment over the forecast period (2025–2035) is expected to be **Stem Cell Collection and Processing**. This growth is attributed to increasing applications in regenerative medicine, rising demand for stem cell transplantation, and ongoing research in cell-based therapies.

The segment is also benefitting from expanding clinical trials and growing awareness about stem cell banking. These trends highlight a dynamic shift in the market, with innovation and personalized medicine driving future demand.

**Figure 1: Us Apheresis Service Market Market, By****service type****, 2024 & 2035 (USD Million)**

### **Us Apheresis Service Market Research Report By Application Insights**

Based on Application, the US Apheresis Service Market has been segmented into Neurological Disorders, Autoimmune Disorders, Hematologic Disorders, Oncology, Metabolic Toxicology Disorders, Infectious Diseases, Cardiovascular Disorders, and Others. The Hematologic Disorders segment held the largest market in 2024.

The Oncology segment is the fastest growing segment during the forecast period. The U.S. Apheresis Service Market, based on application, is segmented into Neurological Disorders, Autoimmune Disorders, Hematologic Disorders, Oncology, Metabolic Toxicology Disorders, Infectious Diseases, Cardiovascular Disorders, and Others.

In 2024, the Hematologic Disorders segment held the largest market share due to the high prevalence of blood-related conditions such as leukemia, lymphoma, and sickle cell disease that require apheresis as part of their treatment. The demand is also driven by increasing awareness and advancements in transfusion medicine.

However, the Oncology segment is projected to be the fastest-growing during the 2025–2035 forecast period. This growth is fueled by the rising incidence of cancer, growing use of apheresis in cell therapy and immunotherapy, and expanding clinical research in oncology-focused treatments.

The market dynamics reflect a growing reliance on apheresis as a supportive and therapeutic tool in both chronic and life-threatening disease management.

### **Us Apheresis Service Market Research Report End User Insights**

Based on End User, the US Apheresis Service Market has been segmented into Hospitals, Blood Banks, Specialty Clinics, Research Laboratories, and Biotechnology Pharmaceutical Companies. The Blood Banks segment held the largest market in 2024.

The Research Laboratories segment is the fastest growing segment during the forecast period. The U.S. Apheresis Service Market, segmented by end user, includes Hospitals, Blood Banks, Specialty Clinics, Research Laboratories, and Biotechnology Pharmaceutical Companies.

In 2024, the Blood Banks segment accounted for the largest market share due to the high demand for blood component separation, donor apheresis procedures, and the growing need for safe and efficient blood supply management. **Blood banks** play a critical role in meeting the needs of patients requiring plasma, platelets, and other blood components.

However, the **Research Laboratories** segment is projected to witness the fastest growth during the forecast period (2025–2035). This is driven by increased investments in biomedical research, advancements in cell therapy and gene therapy, and the growing use of apheresis in experimental treatments and clinical trials.

The expanding focus on personalized medicine and innovation in therapeutic approaches is expected to accelerate demand for apheresis services within research environments.

### **Us Apheresis Service Market Research Report Region Insights**

Based on region, the US Apheresis Service Market has been segmented into North, South, Midwest, and West. South accounted for the largest market share in 2024 and is anticipated to reach USD 757.67 million by 2035.

It is projected to grow at the highest CAGR of 9.63% during the forecast period. The U.S. Apheresis Service Market, based on region, is segmented into North, South, Midwest, and West. In 2024, the South region held the largest market share and is expected to maintain its dominance through 2035.

The market in the South is projected to reach USD 757.67 million by 2035, growing at the highest compound annual growth rate (CAGR) of 9.63% during the forecast period. This growth is driven by a high concentration of healthcare facilities, rising prevalence of chronic diseases.

It is also driven by increasing adoption of advanced apheresis technologies, and supportive state-level healthcare initiatives. Additionally, the presence of major blood banks and research institutions further boosts demand for apheresis services in the region.

The South’s growing population and expanding access to specialized treatments also contribute to its leading position and rapid market expansion within the U.S. apheresis services landscape.

**Figure 2: Us Apheresis Service Market Market, by****Region,****2024 & 2035 (USD Million)**

## **Us Apheresis Service Market Research Report Key Market Players & Competitive Insight**

Many global, Region, and local vendors characterize the Peptides Market. The market is highly competitive, with all the players competing to gain market share. Intense competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront market growth.

The vendors compete based on cost, product quality, reliability, and government regulations. Vendors must provide cost-efficient, high-quality products to survive and succeed in an intensely competitive market.

The major players in the market include VERSITI, Fresenius Medical Care Ag, VITALANT, Carter BLOODCARE, IMPACTLIFE, Mayo Foundation For Medical Education And Research (MFMER), New York Blood Center (NYBC), The American National Red Cross, BIOBRIDGE Global, San Diego Blood Bank And Among Others.

The Us Apheresis Service Market is a consolidated market due to increasing competition, acquisitions, mergers and other strategic market developments and decisions to improve operational effectiveness.

### **Key Companies in the Us Apheresis Service Market Include**

- VERSITI
- Fresenius Medical Care Ag
- VITALANT
- Carter BLOODCARE
- IMPACTLIFE
- Mayo Foundation For Medical Education And Research (MFMER)
- New York Blood Center (NYBC)
- The American National Red Cross
- BIOBRIDGE Global
- San Diego Blood Bank

## **Us Apheresis Service Market Segmentation**

### **Us Apheresis Service Market by Service Type Outlook (USD Million, 2019-2035)**

- Donor/Automated Apheresis
- Therapeutic Apheresis - Plasma Exchange - Red Blood Cell Exchange - Extracorporeal Photopheresis - Leukocytapheresis - Thrombocytapheresis - Erythrocytapheresis - Therapeutic Phlebotomy
- Stem Cell Collection and Processing

### **Us Apheresis Service Market by Application Outlook (USD Million, 2019-2035)**

- Neurological Disorders
- **Autoimmune Disorders**
- Hematologic Disorders
- **Oncology**
- Metabolic Toxicology Disorders
- Infectious Diseases
- Cardiovascular Disorders
- Others

### **Us Apheresis Service Market by End User (USD Million, 2019-2035)**

- Hospitals
- Blood Banks
- Specialty Clinics
- Research Laboratories
- Biotechnology Pharmaceutical Companies

### **Us Apheresis Service Market Research Report Region Outlook**

- US - North - South - Midwest - West

## Market Drivers

### Supportive Regulatory Environment

The regulatory landscape for the apheresis market is becoming increasingly favorable, with government agencies providing support for the development and approval of new apheresis technologies. Streamlined approval processes and funding for research initiatives are encouraging innovation within the industry. For example, the FDA has expedited the review of several apheresis devices, which may lead to quicker market entry for new products. This supportive environment is likely to foster competition and drive advancements in apheresis technologies, ultimately benefiting patients and healthcare providers alike. As a result, the apheresis market is expected to expand, with new entrants and established companies alike capitalizing on these regulatory advantages.

### Advancements in Apheresis Technology

Technological innovations in apheresis equipment and techniques are transforming the apheresis market. The introduction of automated apheresis systems and improved blood component separation technologies enhances the efficiency and safety of procedures. For instance, the latest devices can process blood components with greater precision, reducing the risk of complications. The market for apheresis devices is projected to reach $2 billion by 2026, reflecting a compound annual growth rate (CAGR) of 8%. These advancements not only improve patient care but also expand the range of conditions that can be treated through apheresis, thereby driving growth in the apheresis market.

### Growing Awareness of Apheresis Benefits

There is an increasing awareness among healthcare professionals and patients regarding the benefits of apheresis therapies. Educational initiatives and outreach programs are contributing to a better understanding of how apheresis can effectively treat various medical conditions. This heightened awareness is likely to lead to an increase in the number of procedures performed, thereby boosting the apheresis market. As more patients seek alternative treatment options, the industry may experience a shift towards personalized medicine, where apheresis is tailored to individual patient needs. This trend could potentially enhance the market's growth trajectory, as healthcare providers recognize the value of apheresis in comprehensive treatment plans.

### Increasing Prevalence of Chronic Diseases

The rising incidence of chronic diseases such as cancer, autoimmune disorders, and hematological conditions is a primary driver for the apheresis market. As these diseases often require therapeutic apheresis procedures, the demand for such treatments is expected to grow. According to recent data, approximately 60% of patients undergoing apheresis are treated for chronic conditions. This trend indicates a significant market opportunity, as healthcare providers increasingly adopt apheresis technologies to manage these diseases effectively. The apheresis market is likely to see a surge in demand for innovative apheresis devices and procedures, as healthcare systems strive to improve patient outcomes and reduce healthcare costs associated with chronic disease management.

### Rising Demand for Plasma-Derived Therapies

The increasing demand for plasma-derived therapies is significantly impacting the apheresis market. As the need for immunoglobulins, clotting factors, and other plasma products rises, apheresis procedures become essential for collecting and processing plasma. The market for plasma-derived therapies is projected to grow at a CAGR of 9% over the next five years, indicating a robust demand for apheresis services. This trend is likely to drive investments in apheresis technologies and facilities, as healthcare providers seek to meet the growing needs of patients requiring these life-saving therapies. Consequently, the apheresis market is poised for substantial growth as it adapts to the evolving landscape of plasma therapy.

## Future Outlook

The [Apheresis Market](https://www.marketresearchfuture.com/reports/apheresis-market-1508) is projected to grow at a 9.3% CAGR from 2025 to 2035, driven by technological advancements, increasing demand for blood components, and rising chronic diseases.

**New opportunities:**

- Development of automated apheresis systems for enhanced efficiency.
- Expansion of apheresis services in outpatient settings.
- Partnerships with hospitals for integrated blood management solutions.

By 2035, the apheresis market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Type: Therapeutic Apheresis (Largest) vs. Donor Apheresis (Fastest-Growing)

In the US apheresis market, the therapeutic apheresis segment dominates with a substantial share, driven by the increasing prevalence of chronic diseases and the growing demand for plasma-derived therapies. This segment's robust performance is underpinned by advancements in technology and strategic initiatives from key players, enhancing operational efficiencies and patient outcomes.

Conversely, donor apheresis is emerging as the fastest-growing segment due to the rise in blood donations and the expanding awareness of its importance in medical treatment. Factors such as innovative donor engagement strategies and public health campaigns are stimulating growth, making it a critical component of the market landscape as it adapts to meet rising healthcare needs.

Therapeutic Apheresis (Dominant) vs. Donor Apheresis (Emerging)

Therapeutic apheresis is characterized by its significant role in treating various medical conditions, including autoimmune diseases and hematological disorders. This segment leverages advanced technologies to provide effective treatment options, positioning itself as the cornerstone of apheresis procedures. On the other hand, donor apheresis serves as the emerging segment, capitalizing on the increasing public engagement in blood and plasma donation. It is marked by efforts to enhance donor experience and retention, supported by technological innovations that facilitate the collection process. Both segments demonstrate unique contributions to the US apheresis market, balancing established therapeutic applications with new growth opportunities in donor participation.

### By Application: Cancer Treatment (Largest) vs. Autoimmune Disorders (Fastest-Growing)

In the US apheresis market, the application of apheresis technologies is significantly skewed towards Cancer Treatment, which holds the largest market share among various applications. Renal Disorders and Neurological Disorders also contribute noticeably but are trailing behind Cancer Treatment. Autoimmune Disorders, although smaller in comparison, are increasingly recognized as an important application, reflecting a diverse utilization of apheresis procedures across different medical conditions.

The growth trends within the US apheresis market are largely driven by advancements in treatment methodologies for Cancer and Autoimmune Disorders. The increasing prevalence of cancer cases is propelling the demand for apheresis in this sector, whereas the emerging recognition of apheresis in treating autoimmune conditions is positioning it as the fastest-growing application. Additionally, ongoing research and development initiatives are further enhancing the effectiveness and efficiency of apheresis procedures in these areas.

Cancer Treatment (Dominant) vs. Autoimmune Disorders (Emerging)

Cancer Treatment serves as the dominant application segment within the US apheresis market, primarily due to its established protocols and widespread acceptance in clinical settings. The techniques employed in this area are highly refined, providing effective treatment options for various cancer types. On the other hand, Autoimmune Disorders represent an emerging segment that is rapidly gaining traction. With a growing body of evidence supporting the efficacy of apheresis in managing conditions such as lupus and rheumatoid arthritis, this segment is poised for accelerated growth. The shift in clinical focus towards more personalized medicine approaches is also favorably impacting the use of apheresis in autoimmune disorder treatments, making it a significant area of interest for future market developments.

### By End User: Blood Donation Centers (Largest) vs. Hospitals (Fastest-Growing)

In the US apheresis market, Blood Donation Centers hold the largest market share, emphasizing their critical role in blood collection and component separation. Hospitals also have significant representation, providing crucial apheresis procedures for patients needing therapies. Research Laboratories, while important, occupy a smaller share as they primarily focus on studies and advancements in apheresis technology rather than high-volume applications.

Growth trends indicate that Blood Donation Centers will continue to thrive, bolstered by increasing awareness and organizational support. Hospitals are expected to grow the fastest due to rising patient demand for therapeutic apheresis, driven by the prevalence of chronic diseases. Research Laboratories are also key in pushing innovation, thus indirectly supporting the broader market growth.

Blood Donation Centers (Dominant) vs. Hospitals (Emerging)

Blood Donation Centers are established as the dominant players in the US apheresis market, emphasizing their importance in the routine collection of blood components. They are equipped with advanced technologies that enhance efficiency and safety during collection procedures. Hospitals, on the other hand, represent an emerging segment that is rapidly adapting to the demand for therapeutic apheresis treatments, positioning themselves as vital healthcare providers. The integration of new technologies and treatment methodologies in hospitals is expected to elevate their market position. Both segments are pivotal in meeting the increasing demand for apheresis, contributing to the overall advancements in transfusion medicine.

### By Procedure Type: Automated Apheresis (Largest) vs. Manual Apheresis (Fastest-Growing)

In the US apheresis market, the distribution of market share between automated and manual apheresis clearly positions automated apheresis as the predominant player. Automated apheresis accounts for a significant majority of the market share, driven by technological advancements and a growing preference among healthcare providers for efficiency and better patient outcomes. Conversely, manual apheresis, although having a smaller share, is witnessing a surge in demand as it offers flexibility and is favored in specific clinical scenarios.

Across the industry, automated apheresis is set to continue its dominance owing to trends such as increasing adoption of advanced medical technologies and improvements in procedures that cater to patient-specific needs. Manual apheresis is also rapidly gaining traction due to its cost-effectiveness and the personalized approach it enables, appealing especially to outpatient settings. The combined growth of both segments illustrates the diverse strategies employed in patient care and the evolution of apheresis practices in the US market.

Procedure Type: Automated Apheresis (Dominant) vs. Manual Apheresis (Emerging)

Automated apheresis is characterized by its use of sophisticated machinery that allows for precise separation and collection of blood components. This technique not only increases the efficiency of blood collection but also enhances the patient experience by reducing the time required for the procedure. As the dominant segment, automated apheresis is backed by ongoing innovations and an increasing number of applications in various therapeutic areas. In contrast, manual apheresis operates through conventional methods that require skilled clinicians to perform complex tasks, making it slower but often preferred in situations where automation is not feasible. The emerging appeal of manual apheresis lies in its cost-effectiveness and ability to handle specific medical conditions with a tailored approach.

## Competitive Benchmarking

The apheresis market exhibits a dynamic competitive landscape characterized by innovation and strategic partnerships. Key players such as Fresenius Kabi (Germany), Terumo BCT (Japan), and Haemonetics Corporation (US) are actively shaping the market through their distinct operational focuses. Fresenius Kabi (Germany) emphasizes product innovation and has recently expanded its portfolio to include advanced apheresis technologies, which enhances its competitive edge. Terumo BCT (Japan) is strategically positioned through its commitment to regional expansion, particularly in North America, where it aims to increase its market share. Meanwhile, Haemonetics Corporation (US) focuses on digital transformation, integrating AI-driven solutions into its apheresis systems, thereby improving efficiency and patient outcomes. Collectively, these strategies contribute to a competitive environment that is increasingly driven by technological advancements and customer-centric solutions.
The business tactics employed by these companies reflect a concerted effort to optimize operations and enhance market presence. Localizing manufacturing has become a prevalent strategy, allowing companies to reduce costs and improve supply chain efficiency. The market structure appears moderately fragmented, with several key players exerting influence over various segments. This fragmentation fosters competition, compelling companies to innovate continuously and differentiate their offerings.
In October 2025, Fresenius Kabi (Germany) announced the launch of a new apheresis device designed to enhance the efficiency of blood component collection. This strategic move is significant as it not only reinforces the company's commitment to innovation but also positions it to capture a larger share of the growing demand for apheresis procedures in the US. The introduction of this device is expected to streamline operations for healthcare providers, thereby improving patient care.
In September 2025, Terumo BCT (Japan) entered into a partnership with a leading US blood center to enhance its apheresis services. This collaboration aims to leverage Terumo's advanced technology and the blood center's extensive network to improve blood collection efficiency. The strategic importance of this partnership lies in its potential to expand Terumo's footprint in the US market while simultaneously addressing the increasing demand for blood products.
In August 2025, Haemonetics Corporation (US) unveiled a new AI-driven analytics platform designed to optimize apheresis procedures. This platform is expected to provide real-time insights into patient data, thereby enhancing decision-making for healthcare providers. The strategic relevance of this development is underscored by the growing trend towards data-driven healthcare solutions, which are likely to become a cornerstone of competitive differentiation in the apheresis market.
As of November 2025, the competitive trends in the apheresis market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances are playing a crucial role in shaping the current landscape, enabling companies to pool resources and expertise. Looking ahead, it is anticipated that competitive differentiation will evolve, shifting from price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This transition underscores the importance of adaptability and forward-thinking strategies in maintaining a competitive edge in the apheresis market.

## Report Scope

| MARKET SIZE 2024 | 252.0(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 275.44(USD Million) |
| MARKET SIZE 2035 | 670.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 9.3% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Fresenius Kabi (DE), Terumo BCT (JP), Haemonetics Corporation (US), Grifols S.A. (ES), Cellerant Therapeutics (US), Kawasumi Laboratories (JP), Asahi Kasei Medical (JP), Medtronic (IE), Blood Centers of America (US) |
| Segments Covered | Type, Application, End User, Procedure Type |
| Key Market Opportunities | Advancements in automated apheresis systems enhance efficiency and patient outcomes in therapeutic applications. |
| Key Market Dynamics | Technological advancements and regulatory changes drive growth and competition in the apheresis market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What is the current valuation of the US apheresis market in 2025?**
A: The US apheresis market valuation is projected to reach $252.0 Million in 2025.

**Q: What is the expected CAGR for the US apheresis market from 2025 to 2035?**
A: The expected CAGR for the US apheresis market during the forecast period 2025 - 2035 is 9.3%.

**Q: Which segment is projected to have the highest valuation in the US apheresis market by 2035?**
A: By 2035, the Cancer Treatment segment is projected to reach $250.0 Million, indicating strong growth.

**Q: What are the key players in the US apheresis market?**
A: Key players in the US apheresis market include Fresenius Kabi, Terumo BCT, Haemonetics Corporation, and Grifols S.A.

**Q: How does the valuation of Therapeutic Apheresis compare to other segments in 2025?**
A: In 2025, Therapeutic Apheresis is valued at $210.0 Million, making it one of the leading segments.

**Q: What is the projected market size for Automated Apheresis by 2035?**
A: The market size for Automated Apheresis is projected to reach $420.0 Million by 2035.

**Q: Which end user segment is expected to dominate the US apheresis market by 2035?**
A: By 2035, Hospitals are expected to dominate the market with a valuation of $250.0 Million.

**Q: What is the valuation of the Plasma Apheresis segment in 2025?**
A: The Plasma Apheresis segment is valued at $150.0 Million in 2025.

**Q: How does the market for Donor Apheresis compare to that of Cell Apheresis in 2025?**
A: In 2025, Donor Apheresis is valued at $180.0 Million, significantly higher than Cell Apheresis at $100.0 Million.

**Q: What applications are driving growth in the US apheresis market?**
A: Applications such as Cancer Treatment and Autoimmune Disorders are driving growth, with valuations of $250.0 Million and $190.0 Million respectively by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-apheresis-market-17897*